Zai Lab Ltd (ZLAB) shares tumbled 5.01% in pre-market trading on Thursday following the release of its second-quarter earnings report. The biopharmaceutical company posted narrower losses but fell short of revenue expectations, disappointing investors.
For the quarter ended June 30, Zai Lab reported a loss of $0.37 per American Depository Share, an improvement from the $0.82 loss per share in the same period last year. This beat the FactSet analyst consensus estimate of a $0.40 loss per share. However, the company's revenue of $109.98 million, while up 9.43% year-over-year, significantly missed the analyst expectations of $125.63 million.
The substantial revenue miss appears to be overshadowing the narrower losses, leading to the negative market reaction. Investors may be concerned about Zai Lab's growth trajectory, given the 12.46% shortfall compared to analyst estimates. As the company continues to navigate the challenging biopharmaceutical landscape, market participants will likely keep a close eye on its ability to meet future revenue targets and progress towards profitability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.